We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.075 | -0.17% | 44.515 | 44.72 | 44.46 | 44.49 | 2,573,393 | 20:43:31 |
From Nov 2023 to May 2024
By Ben Glickman
HilleVax on Thursday named Sean McLoughlin as the vaccine developer's next operating chief.
The Boston-based biopharmaceutical company said that co-founder and current COO Aditya Kohli will become chief business officer as part of a planned transition.
McLoughlin, 52, recently served as global vaccine commercialization lead, RSV at GSK. He has held various roles at GSK over 25 years with the company.
McLoughlin will receive an annual base salary of $450,000, with an annual target bonus of 45% of his salary and a sign-on bonus of $200,000.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 18, 2024 07:34 ET (12:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
